DUFFY BLOOD GROUP, CHEMOKINE RECEPTOR GENE MUTATION

Clinical trials for DUFFY BLOOD GROUP, CHEMOKINE RECEPTOR GENE MUTATION explained in plain language.

Never miss a new study

Get alerted when new DUFFY BLOOD GROUP, CHEMOKINE RECEPTOR GENE MUTATION trials appear

Sign up with your email to follow new studies for DUFFY BLOOD GROUP, CHEMOKINE RECEPTOR GENE MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

Could your blood type change your cancer treatment?

Disease control Not yet recruiting

This study is testing whether personalized dosing guidelines for people with a specific blood type (Duffy null) can help them better tolerate standard cancer treatments. Researchers will enroll 90 people with multiple myeloma or triple-negative breast cancer to see if these tailo…

Matched conditions: DUFFY BLOOD GROUP, CHEMOKINE RECEPTOR GENE MUTATION

Phase: PHASE1 • Sponsor: Andrew Hantel, MD • Aim: Disease control

Last updated Mar 27, 2026 12:40 UTC

DUFFY BLOOD GROUP, CHEMOKINE RECEPTOR GENE MUTATION

Get alerted when new DUFFY BLOOD GROUP, CHEMOKINE RECEPTOR GENE MUTATION trials appear

Could your blood type change your cancer treatment?